Danaher Q1 Revenues up 5 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Danaher today said that its first quarter sales grew 5 percent year over year, while its Life Science & Diagnostics segment grew 2 percent. 

For the three months ended April 3, the Washington-based conglomerate posted sales of $4.87 billion, up from $4.66 billion in the year-ago quarter, and beating the consensus Wall Street estimate of $4.83 billion. 

Core sales improved 5 percent year over year, while acquisitions added 6 percentage points to growth. Currency effects dampened results by 6.5 percent, the firm said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.